This report provides a comprehensive analysis of the global Plasmid DNA CDMO Service market, examining its growth trajectory from 2025 through 2032. Driven by rising demand in gene therapy, cell therapy, and vaccine development, the market is segmented by grade, application, and geography. The study evaluates key industry players, competitive strategies, and regional dynamics across the Americas, APAC, and Europe, offering detailed insights into emerging opportunities and the evolving biotechnological landscape.

Executive Overview

The global Plasmid DNA CDMO (Contract Development and Manufacturing Organization) Service market is projected to experience significant growth from 2025 through 2032, expanding at a steady compound annual growth rate.

Plasmid DNA CDMO services involve providing specialized support for the development, production, and commercialization of plasmid DNA used in biopharmaceutical applications. These services cater to the growing demand for plasmid DNA, which plays a crucial role in gene therapy, cell therapy, vaccines, and other biotechnological advancements.

Regional Market Analysis

Global Outlook

• Global Market: The market is expected to see sustained expansion from 2025 to 2032.
• United States: The market is estimated to increase steadily from 2025 through 2032.
• China: The market is estimated to undergo significant growth between 2025 and 2032.
• Europe: The market is estimated to experience consistent growth from 2025 to 2032.

Market Segmentation

By Type

• Research Grade
• Commercial Grade
• GMP Grade
• Others

By Application

• Preclinical
• Clinical
• Commercial

By Region

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

Competitive Landscape

Market Dynamics

In terms of revenue, the global market is characterized by significant concentration, with the two largest companies holding a substantial portion of the market share in 2025.

Key Players

The following companies have been profiled based on primary expert input and analysis of their coverage, product portfolios, and market penetration:

• Creative Biogene
• AGC Biologics
• Biovian
• GenScript ProBio
• Charles River Laboratories
• PackGene
• Catalent Biologics
• Patheon
• Mycenax Biotech Inc
• VGXI
• Esco Aster
• Eurogentec
• 53Biologics
• SK pharmteco
• Cytovance Biologics
• Aldevron
• Bionova Scientific

About the Report

Research Scope and Methodology

LPI (LP Information)'s newest research report, the “Plasmid DNA CDMO Service Industry Forecast,” reviews total world Plasmid DNA CDMO Service sales in 2025 and provides a comprehensive analysis by region and market sector of projected sales for 2026 through 2032. The report provides a detailed analysis in US$ millions, with sales broken down by region, market sector, and sub-sector.

This study utilizes a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs to offer a highly nuanced view of the current state and future trajectory of the global industry.

Key Insights Provided

This Insight Report offers a comprehensive analysis of the global Plasmid DNA CDMO Service landscape, highlighting:

• Market Trends: Key trends related to product segmentation, company formation, revenue, and market share.
• Corporate Activity: Latest developments and M&A activity.
• Strategic Analysis: An analysis of leading global companies' strategies, focusing on their Plasmid DNA CDMO Service portfolios, capabilities, market entry strategies, market positions, and geographic footprints.
• Growth Opportunities: Evaluation of key market trends, drivers, and affecting factors to highlight emerging pockets of opportunity across type, application, geography, and market size.

• 1 Scope of the Report

  • 1.1 Market Introduction

  • 1.2 Years Considered

  • 1.3 Research Objectives

  • 1.4 Market Research Methodology

  • 1.5 Research Process and Data Source

  • 1.6 Economic Indicators

  • 1.7 Currency Considered

  • 1.8 Market Estimation Caveats

• 2 Executive Summary

  • 2.1 World Market Overview

    • 2.1.1 Global Plasmid DNA CDMO Service Market Size (2021-2032)

    • 2.1.2 Plasmid DNA CDMO Service Market Size CAGR by Region (2021 VS 2025 VS 2032)

    • 2.1.3 World Current & Future Analysis for Plasmid DNA CDMO Service by Country/Region (2021, 2025 & 2032)

  • 2.2 Plasmid DNA CDMO Service Segment by Type

    • 2.2.1 Research Grade

    • 2.2.2 Commercial Grade

    • 2.2.3 GMP Grade

    • 2.2.4 Others

    • 2.2.5 Plasmid DNA CDMO Service Market Size by Type

      • 2.2.5.1 Plasmid DNA CDMO Service Market Size CAGR by Type (2021 VS 2025 VS 2032)
      • 2.2.5.2 Global Plasmid DNA CDMO Service Market Size Market Share by Type (2021-2026)

  • 2.3 Plasmid DNA CDMO Service Segment by Application

    • 2.3.1 Preclinical

    • 2.3.2 Clinical

    • 2.3.3 Commercial

    • 2.3.4 Plasmid DNA CDMO Service Market Size by Application

      • 2.3.4.1 Plasmid DNA CDMO Service Market Size CAGR by Application (2021 VS 2025 VS 2032)
      • 2.3.4.2 Global Plasmid DNA CDMO Service Market Size Market Share by Application (2021-2026)

• 3 Plasmid DNA CDMO Service Market Size by Player

  • 3.1 Plasmid DNA CDMO Service Market Size Market Share by Player

    • 3.1.1 Global Plasmid DNA CDMO Service Revenue by Player (2021-2026)

    • 3.1.2 Global Plasmid DNA CDMO Service Revenue Market Share by Player (2021-2026)

  • 3.2 Global Plasmid DNA CDMO Service Key Players Head office and Products Offered

  • 3.3 Market Concentration Rate Analysis

    • 3.3.1 Competition Landscape Analysis

    • 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

  • 3.4 New Products and Potential Entrants

  • 3.5 Mergers & Acquisitions, Expansion

• 4 Plasmid DNA CDMO Service by Region

  • 4.1 Plasmid DNA CDMO Service Market Size by Region (2021-2026)

  • 4.2 Global Plasmid DNA CDMO Service Annual Revenue by Country/Region (2021-2026)

  • 4.3 Americas Plasmid DNA CDMO Service Market Size Growth (2021-2026)

  • 4.4 APAC Plasmid DNA CDMO Service Market Size Growth (2021-2026)

  • 4.5 Europe Plasmid DNA CDMO Service Market Size Growth (2021-2026)

  • 4.6 Middle East & Africa Plasmid DNA CDMO Service Market Size Growth (2021-2026)

• 5 Americas

  • 5.1 Americas Plasmid DNA CDMO Service Market Size by Country (2021-2026)

  • 5.2 Americas Plasmid DNA CDMO Service Market Size by Type (2021-2026)

  • 5.3 Americas Plasmid DNA CDMO Service Market Size by Application (2021-2026)

  • 5.4 United States

  • 5.5 Canada

  • 5.6 Mexico

  • 5.7 Brazil

• 6 APAC

  • 6.1 APAC Plasmid DNA CDMO Service Market Size by Region (2021-2026)

  • 6.2 APAC Plasmid DNA CDMO Service Market Size by Type (2021-2026)

  • 6.3 APAC Plasmid DNA CDMO Service Market Size by Application (2021-2026)

  • 6.4 China

  • 6.5 Japan

  • 6.6 South Korea

  • 6.7 Southeast Asia

  • 6.8 India

  • 6.9 Australia

• 7 Europe

  • 7.1 Europe Plasmid DNA CDMO Service Market Size by Country (2021-2026)

  • 7.2 Europe Plasmid DNA CDMO Service Market Size by Type (2021-2026)

  • 7.3 Europe Plasmid DNA CDMO Service Market Size by Application (2021-2026)

  • 7.4 Germany

  • 7.5 France

  • 7.6 UK

  • 7.7 Italy

  • 7.8 Russia

• 8 Middle East & Africa

  • 8.1 Middle East & Africa Plasmid DNA CDMO Service by Region (2021-2026)

  • 8.2 Middle East & Africa Plasmid DNA CDMO Service Market Size by Type (2021-2026)

  • 8.3 Middle East & Africa Plasmid DNA CDMO Service Market Size by Application (2021-2026)

  • 8.4 Egypt

  • 8.5 South Africa

  • 8.6 Israel

  • 8.7 Turkey

  • 8.8 GCC Countries

• 9 Market Drivers, Challenges and Trends

  • 9.1 Market Drivers & Growth Opportunities

  • 9.2 Market Challenges & Risks

  • 9.3 Industry Trends

• 10 Global Plasmid DNA CDMO Service Market Forecast

  • 10.1 Global Plasmid DNA CDMO Service Forecast by Region (2027-2032)

    • 10.1.1 Global Plasmid DNA CDMO Service Forecast by Region (2027-2032)

    • 10.1.2 Americas Plasmid DNA CDMO Service Forecast

    • 10.1.3 APAC Plasmid DNA CDMO Service Forecast

    • 10.1.4 Europe Plasmid DNA CDMO Service Forecast

    • 10.1.5 Middle East & Africa Plasmid DNA CDMO Service Forecast

  • 10.2 Americas Plasmid DNA CDMO Service Forecast by Country (2027-2032)

    • 10.2.1 United States Market Plasmid DNA CDMO Service Forecast

    • 10.2.2 Canada Market Plasmid DNA CDMO Service Forecast

    • 10.2.3 Mexico Market Plasmid DNA CDMO Service Forecast

    • 10.2.4 Brazil Market Plasmid DNA CDMO Service Forecast

  • 10.3 APAC Plasmid DNA CDMO Service Forecast by Region (2027-2032)

    • 10.3.1 China Plasmid DNA CDMO Service Market Forecast

    • 10.3.2 Japan Market Plasmid DNA CDMO Service Forecast

    • 10.3.3 Korea Market Plasmid DNA CDMO Service Forecast

    • 10.3.4 Southeast Asia Market Plasmid DNA CDMO Service Forecast

    • 10.3.5 India Market Plasmid DNA CDMO Service Forecast

    • 10.3.6 Australia Market Plasmid DNA CDMO Service Forecast

  • 10.4 Europe Plasmid DNA CDMO Service Forecast by Country (2027-2032)

    • 10.4.1 Germany Market Plasmid DNA CDMO Service Forecast

    • 10.4.2 France Market Plasmid DNA CDMO Service Forecast

    • 10.4.3 UK Market Plasmid DNA CDMO Service Forecast

    • 10.4.4 Italy Market Plasmid DNA CDMO Service Forecast

    • 10.4.5 Russia Market Plasmid DNA CDMO Service Forecast

  • 10.5 Middle East & Africa Plasmid DNA CDMO Service Forecast by Region (2027-2032)

    • 10.5.1 Egypt Market Plasmid DNA CDMO Service Forecast

    • 10.5.2 South Africa Market Plasmid DNA CDMO Service Forecast

    • 10.5.3 Israel Market Plasmid DNA CDMO Service Forecast

    • 10.5.4 Turkey Market Plasmid DNA CDMO Service Forecast

  • 10.6 Global Plasmid DNA CDMO Service Forecast by Type (2027-2032)

  • 10.7 Global Plasmid DNA CDMO Service Forecast by Application (2027-2032)

    • 10.7.1 GCC Countries Market Plasmid DNA CDMO Service Forecast

• 11 Key Players Analysis

  • 11.1 Creative Biogene

    • 11.1.1 Creative Biogene Company Information

    • 11.1.2 Creative Biogene Plasmid DNA CDMO Service Product Offered

    • 11.1.3 Creative Biogene Plasmid DNA CDMO Service Revenue, Gross Margin and Market Share (2021-2026)

    • 11.1.4 Creative Biogene Main Business Overview

    • 11.1.5 Creative Biogene Latest Developments

  • 11.2 AGC Biologics

    • 11.2.1 AGC Biologics Company Information

    • 11.2.2 AGC Biologics Plasmid DNA CDMO Service Product Offered

    • 11.2.3 AGC Biologics Plasmid DNA CDMO Service Revenue, Gross Margin and Market Share (2021-2026)

    • 11.2.4 AGC Biologics Main Business Overview

    • 11.2.5 AGC Biologics Latest Developments

  • 11.3 Biovian

    • 11.3.1 Biovian Company Information

    • 11.3.2 Biovian Plasmid DNA CDMO Service Product Offered

    • 11.3.3 Biovian Plasmid DNA CDMO Service Revenue, Gross Margin and Market Share (2021-2026)

    • 11.3.4 Biovian Main Business Overview

    • 11.3.5 Biovian Latest Developments

  • 11.4 GenScript ProBio

    • 11.4.1 GenScript ProBio Company Information

    • 11.4.2 GenScript ProBio Plasmid DNA CDMO Service Product Offered

    • 11.4.3 GenScript ProBio Plasmid DNA CDMO Service Revenue, Gross Margin and Market Share (2021-2026)

    • 11.4.4 GenScript ProBio Main Business Overview

    • 11.4.5 GenScript ProBio Latest Developments

  • 11.5 Charles River Laboratories

    • 11.5.1 Charles River Laboratories Company Information

    • 11.5.2 Charles River Laboratories Plasmid DNA CDMO Service Product Offered

    • 11.5.3 Charles River Laboratories Plasmid DNA CDMO Service Revenue, Gross Margin and Market Share (2021-2026)

    • 11.5.4 Charles River Laboratories Main Business Overview

    • 11.5.5 Charles River Laboratories Latest Developments

  • 11.6 PackGene

    • 11.6.1 PackGene Company Information

    • 11.6.2 PackGene Plasmid DNA CDMO Service Product Offered

    • 11.6.3 PackGene Plasmid DNA CDMO Service Revenue, Gross Margin and Market Share (2021-2026)

    • 11.6.4 PackGene Main Business Overview

    • 11.6.5 PackGene Latest Developments

  • 11.7 Catalent Biologics

    • 11.7.1 Catalent Biologics Company Information

    • 11.7.2 Catalent Biologics Plasmid DNA CDMO Service Product Offered

    • 11.7.3 Catalent Biologics Plasmid DNA CDMO Service Revenue, Gross Margin and Market Share (2021-2026)

    • 11.7.4 Catalent Biologics Main Business Overview

    • 11.7.5 Catalent Biologics Latest Developments

  • 11.8 Patheon

    • 11.8.1 Patheon Company Information

    • 11.8.2 Patheon Plasmid DNA CDMO Service Product Offered

    • 11.8.3 Patheon Plasmid DNA CDMO Service Revenue, Gross Margin and Market Share (2021-2026)

    • 11.8.4 Patheon Main Business Overview

    • 11.8.5 Patheon Latest Developments

  • 11.9 Mycenax Biotech Inc

    • 11.9.1 Mycenax Biotech Inc Company Information

    • 11.9.2 Mycenax Biotech Inc Plasmid DNA CDMO Service Product Offered

    • 11.9.3 Mycenax Biotech Inc Plasmid DNA CDMO Service Revenue, Gross Margin and Market Share (2021-2026)

    • 11.9.4 Mycenax Biotech Inc Main Business Overview

    • 11.9.5 Mycenax Biotech Inc Latest Developments

  • 11.10 VGXI

    • 11.10.1 VGXI Company Information

    • 11.10.2 VGXI Plasmid DNA CDMO Service Product Offered

    • 11.10.3 VGXI Plasmid DNA CDMO Service Revenue, Gross Margin and Market Share (2021-2026)

    • 11.10.4 VGXI Main Business Overview

    • 11.10.5 VGXI Latest Developments

  • 11.11 Esco Aster

    • 11.11.1 Esco Aster Company Information

    • 11.11.2 Esco Aster Plasmid DNA CDMO Service Product Offered

    • 11.11.3 Esco Aster Plasmid DNA CDMO Service Revenue, Gross Margin and Market Share (2021-2026)

    • 11.11.4 Esco Aster Main Business Overview

    • 11.11.5 Esco Aster Latest Developments

  • 11.12 Eurogentec

    • 11.12.1 Eurogentec Company Information

    • 11.12.2 Eurogentec Plasmid DNA CDMO Service Product Offered

    • 11.12.3 Eurogentec Plasmid DNA CDMO Service Revenue, Gross Margin and Market Share (2021-2026)

    • 11.12.4 Eurogentec Main Business Overview

    • 11.12.5 Eurogentec Latest Developments

  • 11.13 53Biologics

    • 11.13.1 53Biologics Company Information

    • 11.13.2 53Biologics Plasmid DNA CDMO Service Product Offered

    • 11.13.3 53Biologics Plasmid DNA CDMO Service Revenue, Gross Margin and Market Share (2021-2026)

    • 11.13.4 53Biologics Main Business Overview

    • 11.13.5 53Biologics Latest Developments

  • 11.14 SK pharmteco

    • 11.14.1 SK pharmteco Company Information

    • 11.14.2 SK pharmteco Plasmid DNA CDMO Service Product Offered

    • 11.14.3 SK pharmteco Plasmid DNA CDMO Service Revenue, Gross Margin and Market Share (2021-2026)

    • 11.14.4 SK pharmteco Main Business Overview

    • 11.14.5 SK pharmteco Latest Developments

  • 11.15 Cytovance Biologics

    • 11.15.1 Cytovance Biologics Company Information

    • 11.15.2 Cytovance Biologics Plasmid DNA CDMO Service Product Offered

    • 11.15.3 Cytovance Biologics Plasmid DNA CDMO Service Revenue, Gross Margin and Market Share (2021-2026)

    • 11.15.4 Cytovance Biologics Main Business Overview

    • 11.15.5 Cytovance Biologics Latest Developments

  • 11.16 Aldevron

    • 11.16.1 Aldevron Company Information

    • 11.16.2 Aldevron Plasmid DNA CDMO Service Product Offered

    • 11.16.3 Aldevron Plasmid DNA CDMO Service Revenue, Gross Margin and Market Share (2021-2026)

    • 11.16.4 Aldevron Main Business Overview

    • 11.16.5 Aldevron Latest Developments

  • 11.17 Bionova Scientific

    • 11.17.1 Bionova Scientific Company Information

    • 11.17.2 Bionova Scientific Plasmid DNA CDMO Service Product Offered

    • 11.17.3 Bionova Scientific Plasmid DNA CDMO Service Revenue, Gross Margin and Market Share (2021-2026)

    • 11.17.4 Bionova Scientific Main Business Overview

    • 11.17.5 Bionova Scientific Latest Developments

• 12 Research Findings and Conclusion